Plaintiff
1 case as plaintiff.
Dr. Falk Pharma GmbH is a privately held, family-owned German pharmaceutical company founded in 1960. Headquartered in Freiburg, Germany, the company specializes in digestive and metabolic medicine. While some sources estimate around 200-400 employees, others report a global workforce of approximately 1,000 to 1,550. A 2018 report stated revenue of around €420 million. The company has multiple international subsidiaries, including in Europe and Australia.
The company develops and markets pharmaceutical products for a range of gastrointestinal and hepatobiliary disorders. Its core product lines provide therapies for conditions such as inflammatory bowel disease, eosinophilic esophagitis (EoE), cholestatic liver diseases, constipation, and diarrhea. Notable products include Budenofalk®, Salofalk®, and Ursofalk®. The company's product Jorveza® was approved as the first therapy for eosinophilic esophagitis in Europe. Dr. Falk Pharma manufactures its products primarily in Europe.
As an operating company, Dr. Falk Pharma appears in the database as a plaintiff challenging the validity of a competitor's patents. The single tracked case is a Post-Grant Review (PGR) proceeding filed by Dr. Falk Pharma against Ellodi Pharmaceuticals, L.P. at the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB). This posture, with one plaintiff case and zero defendant cases, is consistent with an operating company proactively challenging patents it may see as a barrier to its own products.
The notable case, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., involves a challenge to a patent for orally administered corticosteroid compositions for treating eosinophilic esophagitis. Dr. Falk Pharma is seeking to bring its own EoE treatment, Jorveza®, to the U.S. market. The PTAB filing argues that the claims of Ellodi's patent are unpatentable. This action is part of a broader series of patent challenges Dr. Falk Pharma has filed against Ellodi concerning related patents for orally disintegrating tablets.
Watchlist
Email-only, free, anonymous. We'll notify you when Dr. Falk Pharma GmbH files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Post-Grant Review (PGR) filed by petitioner Dr. Falk Pharma GmbH, challenging the validity of claims 1-34 of the '598 patent. The grounds for the challenge include lack of written description and anticipation.